Reduction in the Free Androgen Index in Overweight Women After Sixty Days of a Low Glycemic Diet

Abstract

Background Hyperandrogenism is among the most common endocrine disorders in women. Clinically, it manifests as hirsutism, acne, and alopecia. A healthy lifestyle, including nutritious dietary patterns and physical activity, may influence the clinical manifestation of the disease. This study determined the effect of a low-glycemic index anti-inflammatory diet on testosterone levels and sex hormone-binding globulin (SHBG) and clinical symptoms in hyperandrogenic women at their reproductive age.

Methods The study included 44 overweight and obese women diagnosed with hyperandrogenism. The anthropometrics (weight, height, body mass index, waist circumference, hip circumference), physical activity, and dietary habits were assessed using valid questionnaires, scales, stadiometer, and tape meter. The significant p-value was <0.001. Serum testosterone and SHBG levels were measured using automated immunoassay instruments.

Results The intervention based on a low-glycemic index diet with anti-inflammatory elements and slight energy deficit decreased total testosterone levels (p<0.003), increased SHBG levels (p<0.001), and decreased the free androgen index (FAI; p<0.001). Post-intervention, overall well-being was much higher than in the pre-intervention period (p<0.001), and stress was diminished (p<0.001). Western nutritional patterns positively correlate with clinical hyperandrogenism progression, whereas several factors of the low-glycemic index diet with anti-inflammatory elements and slight energy deficit positively associate with reduced clinical hyperandrogenism symptoms.

Conclusions In overweight and obese women, proper selection of diet, introduction of moderate physical activity, and reduction in weight, stress factors, and alcohol consumption translate into several positive effects, including reduced FAI and symptoms such as acne, hirsutism, menstrual disorders, and infertility.

Key words

hyperandrogenism - diet - anti-inflammatory - testosterone - sex hormone - binding globulin - free androgen index

Publication History

Received: 28 April 2023

Accepted: 06 August 2023

Article published online:
18 January 2024

• References

• 1 Azziz R, Carmina E, Dewailly D. et al. Task force on the phenotype of the polycystic ovary syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril 2009; 91: 456-488
• 2 Carmina E, Rosato F, Jannì A. et al. Extensive clinical experience: Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006; 91: 2-6
• 3 Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 24: 1223-1236
• 4 Hatch R, Rosenfield RL, Kim MH. et al. Hirsutism: Implications, etiology and management. Am J Obstet Gynecol 1981; 140: 815
• 5 Goldzieher JW. Polycystic ovary disease. Fertil Steril 1981; 35: 371
• 6 Maroulis GB. Evaluation of hirsutism and hyperandro-genemia. Fertil Steril 36: 273
• 7 Taylor Sl, Dons RF, Hernandez E. et al. Insulin resistance associated with androgen excess in women with autoantibodies to the insulin receptor. Ann Intern Med 1982; 97: 851
• 8 Barbieri RL, Ryan KJ. Hyperandrogenism, insulin resistance and acanthosis nigricans syndrome: A common endocrinopathy with distinct pathophysiological features. Am J Obstet Gynecol 1983; 147: 90
• 9 Poretsky L, Cataldo NA, Rosenwaks Z. et al. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 535-582
• 10 Schröder AK, Tauchert S, Ortmann O. et al. Insulin resistance in patients with polycystic ovary syndrome. Ann Med 2004; 36: 426-439
• 11 Goodman NF, Cobin RH, Futterweit W. et al. American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1. Endocr Pract 2015; 21: 1291-1300
• 12 Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001; 7: 522-525
• 13 Yildiz BO. Diagnosis of hyperandrogenism: Clinical criteria. Best Pract Res Clin Endocrinol Metab 2006; 20: 167-176
• 14 McKnight E. The prevalence of hirsutism in young women. Lancet 1964; 1: 410-413
• 15 Knochenhauer ES, Key TJ, Kahsar-Miller M. et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab 1998; 83: 3078-3082
• 16 Sonino N, Fava GA, Mani E. et al. Quality of life of hirsute women. Postgrad Med J 1993; 69: 186-189
• 17 Girman CJ, Hartmaier S, Roberts J. et al. Patient-perceived importance of negative effects of androgenetic alopecia in women. J Womens Health Gend Based Med 1999; 8: 1091-1095
• 18 Marshburn PB, Carr BR. Hirsutism and virilization. A systematic approach to benign and potentially serious causes. Postgrad Med 1995; 97: 99-106
• 19 Norman RJ, Noakes M, Wu R. et al. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 2004; 10: 267-280
• 20 Sheehan MT. Polycystic ovarian syndrome: Diagnosis and management. Clin Med Res 2004; 2: 13-27
• 21 Sigal RJ, Armstrong MJ, Bacon SL. et al Diabetes Canada Clinical Practice Guidelines Expert Committee, Physical Activity and Diabetes. Can J Diabetes 2018; 42 Suppl 1 S54-S63
• 22 Stamets K, Taylor DS, Kunselman A. et al. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 630-637
• 23 Milewicz A, Kudła M, Spaczyński RZ. et al. The polycystic ovary syndrome: A position statement from the Polish Society of Endocrinology, the Polish Society of Gynaecologists and Obstetricians, and the Polish Society of Gynaecological Endocrinology. Endokrynol Pol 2018; 69: 04
• 24 Cowan S, Lim S, Alycia C. et al. Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity. BMC Endocr Disord 2023; 23: 14
• 25 Moran LJ, Ko H, Misso M. et al. Dietary composition in the treatment of polycystic ovary syndrome: A systematic review to inform evidence‑based guidelines. J Acad Nutr Diet 2013; 113: 520-545
• 26 Teede HJ, Misso ML, Costello MF. et al. Recommendations from the international evidence‑based guideline for the as sessment and management of polycystic ovary syndrome. Hum Reprod 2018; 33: 1602-1618
• 27 Atkinson FS, Foster-Powell K, Brand-Miller JC. International tables of glycemic index and glycemic load values: 2008. Diabetes Care 2008; 31: 2281-2283
• 28 Thompson FE, Subar AF. Dietary Assessment Methodology. In: Coulston AM, Boushey CJ, Ferruzzi MG, eds. Nutrition in the prevention and treatment of disease. San Diego, CA: Academic Press; 2013: 5-46
• 29 World Health Organization. Expert Committee on Physical Status: The use and interpretation of anthropometric physical status. 1995
• 30 World Health Organization. Measuring Obesity: Classification and description of anthropometric data. Copenhagen. 1986
• 31 Bray GA. Fat distribution and body weight. Obesity Research 1993; 202-205 etric physical
• 32 Shishehgar F, Mirmiran P, Rahmati M. et al. Does a restricted energy low glycemic index diet have a different effect on overweight women with or without polycystic ovary syndrome?. BMC Endocr Disord 2019; 19: 93
• 33 Salama AA, Amine EK, Salem HA. et al. Anti-inflammatory dietary combo in overweight and obese women with polycystic ovary syndrome. N Am J Med Sci 2015; 7: 310-316
• 34 Kazemi M, Jarrett BY, Vanden Brink H. et al. Obesity, insulin resistance, and hyperandrogenism mediate the link between poor diet quality and ovarian dysmorphology in reproductive-aged women. Nutrients 2020; 12: 1953
• 35 Katcher HI, Kunselman AR, Dmitrovic R. et al. Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome. Fertil Steril 2009; 91: 1175-1182
• 36 Berrino F, Bellati C, Secreto G. et al. Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trial. Cancer Epidemiol Biomarkers Prev 2001; 10: 25-33
• 37 Lim S, Smith CA, Costello MF. et al. Barriers and facilitators to weight management in overweight and obese women living in Australia with PCOS: A qualitative study. BMC Endocr Disord 2019; 19: 106
• 38 Campbell KL, Foster-Schubert KE, Alfano CM. et al. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: Randomized controlled trial. J Clin Oncol 2012; 30: 2314-26PMC3675691
• 39 Douglas CC, Gower BA, Darnell BE. et al. Role of diet in the treatment of polycystic ovary syndrome. Fertil Steril 2006; 85: 679-688
• 40 Szczuko M, Malarczyk I, Zapałowska-Chwyć M. Improvement in anthropometric parameters after rational dietary intervention in women with polycystic ovary syndrom as the best method to support treatment. Rocz Panstw Zakl Hig 2017; 68: 409-417
• 41 Onieva-Zafra MD, Fernández-Martínez E, Abreu-Sánchez A. et al. Relationship between diet, menstrual pain and other menstrual characteristics among Spanish students. Nutrients 2020; 12: 1759
• 42 Haqq L, McFarlane J, Dieberg G. et al. Effect of lifestyle intervention on the reproductive endocrine profile in women with polycystic ovarian syndrome: A systematic review and meta-analysis. Endocr Connect 2014; 3: 36-46
• 43 Shafrir AL, Zhang X, Poole EM. et al. The association of reproductive and lifestyle factors with a score of multiple endogenous hormones. Horm Cancer 2014; 5: 324-335
• 44 Legro RS, Dodson WC, Kris-Etherton PM. et al. Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. J Clin Endocrinol Metab 2015; 100: 4048-4058
• 45 Richard S, William C, Dodson A. et al. Benefit of delayed fertility therapy with preconception weight loss over immediate therapy in obese women with PCOS. J Clin Endocrinol Metab 2016; 101: 2658-2666